NasdaqGS - Nasdaq Real Time Price USD

Repare Therapeutics Inc. (RPTX)

Compare

1.6000

-0.1700

(-9.60%)

At close: December 16 at 4:00:00 PM EST

1.6100

+0.01

(+0.62%)

After hours: 7:42:17 PM EST

Top Midday Decliners

Repare Therapeutics (RPTX) reported Thursday results from a phase 1 trial of cancer drugs lunreserti

PREMIUM
MT Newswires 3 days ago

RPTX
-9.60%
INO

CADL
Why Is Repare Therapeutics Stock Trading Lower On Friday?

On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial. Across all tumor types treated at the optimized RP2D (n=67),

Benzinga 3 days ago

RPTX
-9.60%
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results

Repare announced plans to initiate a Phase 3 registrational study for endometrial cancer in the second half of 2025.

GuruFocus.com 3 days ago

RPTX
-9.60%
Repare Therapeutics eyes Phase III cancer study after Mythic trial success

The Phase I expansion trial saw a 25.9% overall response rate (ORR) for endometrial cancer and 37.5% in platinum-resistant ovarian cancer.

Clinical Trials Arena 3 days ago

RPTX
-9.60%
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

CAMBRIDGE, Mass. & MONTREAL, December 12, 2024--Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph1 Gynecologic Expansion Clinical Trial

Business Wire 4 days ago

RPTX
-9.60%
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

CAMBRIDGE, Mass. & MONTREAL, December 10, 2024--Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Business Wire 6 days ago

RPTX
-9.60%
Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts

Repare Therapeutics Inc. ( NASDAQ:RPTX ) shareholders will have a reason to smile today, with the analysts making...

Simply Wall St. last month

RPTX
-9.60%
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

CAMBRIDGE, Mass. & MONTREAL, November 12, 2024--Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Business Wire last month

RPTX
-9.60%
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

CAMBRIDGE, Mass. & MONTREAL, November 07, 2024--Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Business Wire last month

RPTX
-9.60%
Repare Therapeutics’ individualised anaemia management trial shows promise

It is observed that the dose optimisation significantly reduced grade 3 anaemia rates from 51.4% to 22.6%.

Clinical Trials Arena last month

RPTX
-9.60%
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

CAMBRIDGE, Mass. & MONTREAL, October 23, 2024--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Business Wire last month

RPTX
-9.60%
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug

Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.

Zacks 2 months ago

RPTX
-9.60%
AZN

ALNY
Repare Therapeutics doses first subject in Phase I solid tumour trial

The trial's primary objective is to assess the safety and tolerability of RP-3467, both as a monotherapy and in combination with Olaparib.

Clinical Trials Arena 2 months ago

RPTX
-9.60%
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

CAMBRIDGE, Mass. & MONTREAL, October 14, 2024--Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Business Wire 2 months ago

RPTX
-9.60%
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

CAMBRIDGE, Mass. & MONTREAL, September 30, 2024--Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Business Wire 2 months ago

RPTX
-9.60%
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company

Key Insights Significantly high institutional ownership implies Repare Therapeutics' stock price is sensitive to their...

Simply Wall St. 2 months ago

RPTX
-9.60%
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

CAMBRIDGE, Mass. & MONTREAL, September 23, 2024--Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Business Wire 2 months ago

RPTX
-9.60%
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

CAMBRIDGE, Mass. & MONTREAL, September 13, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1/2 TRESR clinical trial during an oral presentation on September 14 at the European Society for Medical Oncology Congress (ESMO), held in Barcelona, Spain.

Business Wire 3 months ago

RPTX
-9.60%
Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets

Repare plans to slash the headcount in its preclinical group and reduce R&D activities as it funnels resources into clinical candidates.

Clinical Trials Arena 3 months ago

RPTX
-9.60%
Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic Landscape

We recently compiled a list of the 10 Best Canadian Penny Stocks to Buy Now. In this article, we are going to take a look at where Repare Therapeutics Inc. (NASDAQ:RPTX) stands against the other Canadian penny stocks. As we navigate the complexities of 2024, Canada’s economic landscape presents a unique blend of challenges and […]

Insider Monkey 3 months ago

RPTX
-9.60%

Performance Overview

Return	RPTX	S&P 500
YTD	-78.08%	+27.34%
1-Year	-76.30%	+28.71%
3-Year	-92.25%	+28.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Repare Therapeutics Inc. (RPTX)

Top Midday Decliners

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results

Repare Therapeutics eyes Phase III cancer study after Mythic trial success

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics’ individualised anaemia management trial shows promise

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug

Repare Therapeutics doses first subject in Phase I solid tumour trial

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets

Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic Landscape

Performance Overview